Stock Commentary - Europe - week to January 7, 2008
7 January 2008
EUROPEAN: bourses were mostly lower in the three-week Christmas and New Year reporting period to December 31, 2007, with the exception of FRANKFURT, where the Xetra Dax was also Europe's best performer for 2007, rising 22% for the year. Among pharmaceutical stocks, Bayer and Merck KGaA were the only gainers, increasing 6.3% and 1.8%, respectively. Reported by the UK's Financial Times, Axa Framlington Health's Deane Donnigan said her overriding investment thesis is to look for companies with products where there is a real value, and these include both the German drugmakers. PARIS saw Sanofi-Aventis underperform with a 2.9% fall, compared with the CAC 40's 2.4% decline while bioMerieux advanced 3.1%. Roche was the worst performer on the ZURICH exchange, with 4.6% downturn, while Novartis was 4.2% lower.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.
Stock Commentary - Europe - week to January 7, 2008
EUROPEAN: bourses were mostly lower in the three-week Christmas and New Year reporting period to December 31, 2007, with the exception of FRANKFURT, where the Xetra Dax was also Europe's best performer for 2007, rising 22% for the year. Among pharmaceutical stocks, Bayer and Merck KGaA were the only gainers, increasing 6.3% and 1.8%, respectively. Reported by the UK's Financial Times, Axa Framlington Health's Deane Donnigan said her overriding investment thesis is to look for companies with products where there is a real value, and these include both the German drugmakers. PARIS saw Sanofi-Aventis underperform with a 2.9% fall, compared with the CAC 40's 2.4% decline while bioMerieux advanced 3.1%. Roche was the worst performer on the ZURICH exchange, with 4.6% downturn, while Novartis was 4.2% lower.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Company News Directory
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
| Headless Content Management with Blaze